title: The hypolipidemic action of bezafibrate therapy in hypertriglyceridemia is mediated by upregulation of lipoprotein lipase: no effects on VLDL substrate affinity to lipolysis or LDL receptor binding.
abstract: Fibrates are regarded as drugs of choice in hypertriglyceridemia (HTG). Downregulation of apolipoprotein (apo) C-III gene expression and upregulation of lipoprotein lipase (LPL) gene expression have been suggested to explain the hypolipidemic action of fibrates. This study was designed to study the effects of bezafibrate therapy on very low density lipoprotein (VLDL) susceptibility to lipolysis, VLDL binding to the low density lipoprotein (LDL) receptor and postheparin LPL activities in patients with HTG. VLDL lipolysis was studied with heparan sulfate proteoglycan-bound LPL. Binding affinity of VLDL to the LDL receptor was determined in J774 cells with 125I-labeled control LDL. Eighteen HTG patients were randomized to receive, in a double-blind placebo-controlled cross-over fashion, 400 mg bezafibrate once daily for 6 weeks. In response to bezafibrate therapy, plasma triglyceride and apoC-III levels decreased by 69 and 42%, respectively. HTG VLDL was lipolyzed less efficiently compared to control VLDL, and lipolysis did not improve by bezafibrate therapy. VLDL binding affinity to the LDL receptor was comparable between the control group and HTG group, and did not change upon bezafibrate therapy. However, the post-heparin LPL activity in the HTG patients increased from 153 to 192 U/l (P = 0.025). A strong inverse relation was observed between the change in LPL activities and the change in triglyceride levels (r = -0.62, P = 0.006). In conclusion, the hypolipidemic action of bezafibrate therapy in HTG may be attributed to increased LPL activity, whereas VLDL susceptibility to lipolysis and LDL receptor binding are not affected.
authors.affiliation: Department of Cardiology, Leiden University Medical Center, The Netherlands.
authors.forename: F H
authors.initials: FH
authors.lastname: de Man
authors.forename: F
authors.initials: F
authors.lastname: de Beer
authors.forename: A
authors.initials: A
authors.lastname: van der Laarse
authors.forename: H
authors.initials: H
authors.lastname: Jansen
authors.forename: J A
authors.initials: JA
authors.lastname: Leuven
authors.forename: J H
authors.initials: JH
authors.lastname: Souverijn
authors.forename: T F
authors.initials: TF
authors.lastname: Vroom
authors.forename: S C
authors.initials: SC
authors.lastname: Schoormans
authors.forename: J C
authors.initials: JC
authors.lastname: Fruchart
authors.forename: L M
authors.initials: LM
authors.lastname: Havekes
authors.forename: A H
authors.initials: AH
authors.lastname: Smelt
mesh_terms: D000328:Adult; D001629:Bezafibrate / Q000008:administration & dosage*; D004311:Double-Blind Method; D004789:Enzyme Activation; D005260:Female; D006801:Humans; D015228:Hypertriglyceridemia / Q000188:drug therapy* / Q000378:metabolism; D000960:Hypolipidemic Agents / Q000008:administration & dosage*; D008066:Lipolysis / Q000187:drug effects; D008071:Lipoprotein Lipase / Q000378:metabolism*; D008079:Lipoproteins, VLDL / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D011973:Receptors, LDL / Q000378:metabolism; D013379:Substrate Specificity; D015854:Up-Regulation
chemical_list: D000960:Hypolipidemic Agents; D008079:Lipoproteins, VLDL; D011973:Receptors, LDL; D008071:Lipoprotein Lipase; D001629:Bezafibrate